CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 102 enrolled
Drug / intervention
IQOSother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05076708
NCT05076708Early Ph 1Completed
CompareCT.gov

The Effects of IQOS Use on Cigarette Smoking Behaviors

University of Pennsylvania·interventional·Posted Oct 13, 2021·Updated Feb 3, 2025

In Brief

A Early Phase 1 clinical trial evaluating IQOS for Smoking and 2 related conditions. Completed, enrolled 102 participants across 1 site.

Detailed Summary

This within-subjects study aims to evaluate the effects of IQOS use on combustible cigarette smoking behaviors among 100 cigarette smokers who completed the study. After measuring baseline cigarette smoking rate, participants will receive an IQOS device and be instructed to use it (versus cigarettes) over a 14-day period. The investigators will also examine which objective and subjective effects of IQOS use predict a complete and incomplete switch from cigarettes to IQOS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking, Cigarette Smoking, Tobacco Use
CountriesUnited States
Collaborators--

Timeline

Early Ph 1CompletedFinished
20222023202420252026
First PostedOct 13, 2021
Enrollment StartAug 26, 2021
Primary CompletionFeb 1, 2024
Study CompletionMay 31, 2024
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 4.7 years ago

Interventions

IQOSother

All participants switch from cigarette smoking to IQOS use for a 14-day phase.